Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron. 

Please follow us:

This post was originally published here